Shawn Tomasello Net Worth

The estimated Net Worth of Shawn Tomasello is at least $2.28 Million dollars as of 30 September 2022. Ms. Tomasello owns over 9,677 units of UroGen Pharma Ltd stock worth over $161,259 and over the last 9 years she sold URGN stock worth over $1,810,597. In addition, she makes $312,698 as Independent Director at UroGen Pharma Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Tomasello URGN stock SEC Form 4 insiders trading

Shawn has made over 7 trades of the UroGen Pharma Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 9,677 units of URGN stock worth $14,999 on 30 September 2022.

The largest trade she's ever made was buying 9,677 units of UroGen Pharma Ltd stock on 30 September 2022 worth over $14,999. On average, Shawn trades about 670 units every 53 days since 2015. As of 30 September 2022 she still owns at least 11,677 units of UroGen Pharma Ltd stock.

You can see the complete history of Ms. Tomasello stock trades at the bottom of the page.

Shawn Tomasello biography

Shawn Cline Tomasello is Independent Director of the Company. Ms. Tomasello most recently served as Chief Commercial Officer of Kite Pharma, Inc. (subsequently Kite, a Gilead Company). Prior to joining Kite, Ms. Tomasello served as Chief Commercial Officer at Pharmacyclics, Inc. Previously, she held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for five brands encompassing 11 indications. Prior to this, she was National Director of Hematology for Rituxan at Genentech. Earlier in her career, Ms. Tomasello held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. She currently serves on the Boards of Centrexion Therapeutics, Oxford BioTherapeutics, Mesoblast, Gamida Cell, and Diplomat Specialty. Ms. Tomasello holds a B.S. degree in marketing from the University of Cincinnati and an M.B.A. from Murray State University, Kentucky. Our Board believes Ms. Tomasello’s leadership and management experience qualifies her to serve on our board of directors.

What is the salary of Shawn Tomasello?

As the Independent Director of UroGen Pharma Ltd, the total compensation of Shawn Tomasello at UroGen Pharma Ltd is $312,698. There are 12 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.

How old is Shawn Tomasello?

Shawn Tomasello is 61, she's been the Independent Director of UroGen Pharma Ltd since 2018. There are 5 older and 10 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.

What's Shawn Tomasello's mailing address?

Shawn's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.

Insiders trading at UroGen Pharma Ltd

Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun, and Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.

What does UroGen Pharma Ltd do?

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.

Complete history of Ms. Tomasello stock trades at Abeona Therapeutics Inc, UroGen Pharma Ltd, Gamida Cell Ltd, Cabaletta Bio Inc, Principia Biopharma, TCR2 Therapeutics, 4D Molecular Therapeutics, and AlloVir

UroGen Pharma Ltd executives and stock owners

UroGen Pharma Ltd executives and other stock owners filed with the SEC include:

• Elizabeth Barrett,
  President, Chief Executive Officer, Director
• Elizabeth A. Barrett,
  Pres, CEO & Director
• Mark Schoenberg,
  Chief Medical Officer
• Ron Bentsur,
  Advisor
• Dr. Mark P. Schoenberg,
  Chief Medical Officer
• Arie Belldegrun,
  Independent Chairman of the Board
• Jason Drew Smith,
  Gen. Counsel & Chief Compliance Officer
• Cynthia Butitta,
  Independent Director
• Kathryn Falberg,
  Independent Director
• Stuart Holden,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Fred Cohen,
  Independent Director
• Shawn Tomasello,
  Independent Director
• Molly Henderson CPA, MBA,
  Chief Financial Officer
• Elyse Seltzer,
  Chief Development Officer
• Polly Murphy,
  Chief Business Officer
• Jeff Bova,
  Chief Commercial Officer
• Jason Smith,
  Chief Compliance Officer, General Counsel
• Jim Ottinger,
  Executive Vice President, Regulatory Affairs and Quality
• Marina Konorty,
  Executive Vice President, Research & Development and Technical Operations
• Molly Henderson,
  Chief Financial Officer, Principal Accounting Officer
• James Ottinger R.ph.,
  Exec. VP of Regulatory Affairs & Quality
• Jeffrey Bova M.B.A.,
  Chief Commercial Officer
• Dr. Sari Prutchi-Sagiv Ph.D.,
  Marketing Director
• Eric Van Zanten,
  Sr. Director of Communications
• Jason Smith,
  Gen. Counsel & Chief Compliance Officer
• Sara Blum Sherman,
  Sr. Director of Investor Relations
• James A. Jr. Robinson,
  Director
• Investments Iv, L.P.Pro Que...,
  
• Stephen Mullennix,
  Chief Operating Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Leana Wen,
  Director
• Dong Kim,
  Chief Financial Officer
• Daniel George Wildman,
  Director